publication date: Jun. 21, 2019

Trials & Tribulations

Lessons from the front lines of value-based care: The OCM’s impact on community oncology

Charles Saunders_edit

By Charles Saunders

CEO, Integra Connect


Nearly three years after its introduction, the CMS’s Oncology Care Model (OCM) remains the most ambitious and far-reaching initiative to shift cancer care toward value-based models.

The impact on community oncology, where almost 55% of U.S. cancer patients receive treatment1, has been especially pronounced. Our experiences supporting the success of one of the largest OCM cohorts—approximately 900 providers and 25,000 patients—has enabled us to aggregate their experiences into a snapshot of the program’s positive impacts, its challenges, and the broader implications for providers, pharma, and payers. 

OCM participants often cite 2018 as the year that value-based cancer care became a financial and clinical reality for them. That’s when they received results for their first two performance periods, covering episodes that started July 1, 2016 through 2017.

What were the primary takeaways?

Positive momentum in cost and quality performance. Practices made steady progress in closing the gap between CMS’s target price for chemo episodes and their actual expenditures. We saw an average 46% improvement among our cohort between the first two performance periods. This resulted from successful efforts to reduce unnecessary ER visits and inpatient stays through interventions such as care navigation and extended office hours, along with positive adjustments for use of novel … Continue reading Lessons from the front lines of value-based care: The OCM’s impact on community oncology

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.